Related Experiment Video
Updated: Jun 22, 2026
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
Published on: February 28, 2021
Plasma levels of 15d-PGJ are not altered in multiple sclerosis
M Comabella1, J M Pradillo, M Fernández
1Unitat de Neuroimmunologia Clínica, CEM-Cat, Hospital Universitari Vall d 'Hebron (HUVH), Barcelona, Spain. mcomabel@ir.vhebron.net
Background:
The 15-deoxi delta prostaglandin J(2) (15d-PGJ(2)) is a peroxisome proliferator-activated receptor-gamma agonist with potent anti-inflammatory properties. It has been suggested that 15d-PGJ(2) may modulate multiple sclerosis (MS).
Methods:
Here, we investigated the plasma levels of 15d-PGJ(2) by enzyme-linked immunoassay in 28 healthy controls and 140 MS patients [30 patients with primary-progressive MS, 28 patients with secondary-progressive MS, and 82 patients with relapsing-remitting MS (28 patients during clinical remission, 25 patients during relapse, and 29 treated with interferon-beta - IFN-beta)].
Results:
Levels of 15d-PGJ(2) were similar between healthy controls and untreated MS patients with different clinical courses of the disease. Treatment with IFN-beta had no effect on levels of 15d-PGJ(2).
Conclusions:
Although these findings suggest that 15d-PGJ(2) is not involved in the acute or chronic phases of the disease, further studies measuring 15d-PGJ(2) in cerebrospinal fluid samples are needed before excluding a role of 15d-PGJ(2) in MS.
Insights
Plasma levels of 15-deoxi delta prostaglandin J(2) (15d-PGJ(2)) were similar in multiple sclerosis (MS) patients and healthy controls. This suggests 15d-PGJ(2) may not play a role in MS disease phases.
Area of Science:
- Immunology
- Neuroscience
- Biochemistry
Background:
- 15-deoxi delta prostaglandin J(2) (15d-PGJ(2)) is a PPAR-gamma agonist with anti-inflammatory effects.
- 15d-PGJ(2) has been hypothesized to influence multiple sclerosis (MS) pathogenesis.
Purpose of the Study:
- To investigate plasma levels of 15d-PGJ(2) in MS patients with various clinical courses.
- To determine if 15d-PGJ(2) levels differ between MS patients and healthy controls.
- To assess the impact of interferon-beta (IFN-beta) treatment on 15d-PGJ(2) levels.
Main Methods:
- Plasma 15d-PGJ(2) levels were measured using enzyme-linked immunoassay.
- Study included 140 MS patients (various subtypes and disease states) and 28 healthy controls.
- Patients included those with primary-progressive MS, secondary-progressive MS, relapsing-remitting MS (remission, relapse, IFN-beta treated).
Main Results:
- Plasma 15d-PGJ(2) levels were comparable between healthy controls and untreated MS patients.
- No significant differences in 15d-PGJ(2) levels were observed across different MS clinical courses.
- Interferon-beta treatment did not alter plasma 15d-PGJ(2) levels.
Conclusions:
- Current findings suggest 15d-PGJ(2) is not implicated in the acute or chronic phases of MS.
- Further research involving cerebrospinal fluid analysis is warranted to definitively exclude a role for 15d-PGJ(2) in MS.
